ctDx Lung

Overview

Resolution Bioscience ctDx Lung targeted next-generation sequencing panel for plasma cell-free DNA in non-small-cell lung cancer PMID:36357680.

Used by

• PMID:36357680 — used to profile plasma ctDNA from 1,127 advanced NSCLC patients across MSK and GenesisCare (Sydney); ctDNA detection rate was 64% (722/1,127), and ctDNA detection was independently associated with shorter OS (HR 2.05, 95% CI 1.74–2.42, P<0.001) PMID:36357680.
• PMID:39147831 — ctDx Lung (21-gene panel) used in an international generalizability cohort of 463 advanced NSCLC patients from MSK and GenesisCare (Sydney), demonstrating transferability of the random survival forest ctDNA-VTE model (c-index 0.67) across assay platforms PMID:39147831.

Notes

• Operationally, only 37/1,919 (2%) ctDx Lung or MSK-ACCESS samples failed vs 13% of tissue sequencing attempts; turnaround was 11 days (IQR 9–14) for ctDx Lung/MSK-ACCESS vs 33 days for MSK-IMPACT PMID:36357680.
• 25% of patients had genomic alterations detected only in ctDNA (not in time-matched tissue), enriched for subclonal resistance drivers such as RICTOR and PIK3CA PMID:36357680.
• ctDx Lung has a small genomic footprint, which limits TMB correlation analyses PMID:36357680.

Sources

• PMID:36357680
• PMID:39147831

This page was processed by crosslinker on 2026-04-11.